JAC Advance Access originally published online on January 6, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy (2003) 51, 367-371
© 2003 The British Society for Antimicrobial Chemotherapy
Monotherapy with mastic does not eradicate Helicobacter pylori infection from mice
1 Institute of Infections and Immunity, Floor C, West Block, University Hospital, Queen’s Medical Centre, University of Nottingham; 2 Division of Microbiology and Infectious Diseases, University of Nottingham, Nottingham NG7 2UH, UK
Received 3 September 2002; returned 10 October 2002; revised 15 October 2002; accepted 23 October 2002
Objective: To determine the ability of mastic monotherapy to eradicate Helicobacter pylori infection from mice.
Materials and methods: The susceptibility of H. pylori SS1 to mastic was assessed by broth dilution determination of the MIC and MBC. Mice were inoculated intragastrically with either a suspension of H. pylori SS1 (n = 70) or brain–heart infusion broth alone (n = 10). Mice were given antimicrobial chemotherapy 4 weeks after infection and were administered the mouse equivalent of either 2 g of mastic twice daily for 7 days or a triple therapy regimen containing the mouse equivalent of 400 mg of metronidazole, 250 mg of clarithromycin and 20 mg of omeprazole twice daily for 7 days. Mice were killed either immediately or 1 month after the completion of treatment, and their stomachs cultured for H. pylori.
Results: The mastic MIC and MBC of H. pylori SS1 were 7.80 and 31.25 mg/L, respectively. The triple therapy regimen eradicated infection from 19 of 20 SS1-infected mice. Mastic failed to eradicate infection from any of the 18 SS1-infected mice (P < 0.001) and there was no signifi- cant reduction in gastric bacterial load in mice treated with this regimen.
Conclusion: Despite reported beneficial effects in ulcer patients and the good in vitro activity of mastic against H. pylori, this compound is unable to eradicate H. pylori infection from mice.
Keywords: mastic, Helicobacter pylori, mouse model, eradication
* Corresponding author. Tel: +44-115-924-9924, ext. 42457; Fax: +44-115-970-9923; E-mail: Peter.Jenks{at}nottingham.ac.uk
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Paraschos, P. Magiatis, S. Mitakou, K. Petraki, A. Kalliaropoulos, P. Maragkoudakis, A. Mentis, D. Sgouras, and A.-L. Skaltsounis In Vitro and In Vivo Activities of Chios Mastic Gum Extracts and Constituents against Helicobacter pylori Antimicrob. Agents Chemother., February 1, 2007; 51(2): 551 - 559. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Bebb, N. Bailey-Flitter, D. Ala'Aldeen, and J. C. Atherton Mastic gum has no effect on Helicobacter pylori load in vivo J. Antimicrob. Chemother., September 1, 2003; 52(3): 522 - 523. [Abstract] [Full Text] [PDF]
|
|